Predicting Response to Vedolizumab in Inflammatory Bowel Disease
Author:
Publisher
Frontiers Media SA
Subject
General Medicine
Reference33 articles.
1. Vedolizumab as induction and maintenance therapy for Crohn's disease;Sandborn;N Engl J Med,2013
2. Vedolizumab as induction and maintenance therapy for ulcerative colitis;Feagan;N Engl J Med.,2013
3. The real-world effectiveness and safety of vedolizumab for moderate-severe crohn's disease: results from the US VICTORY consortium;Dulai;Am J Gastroenterol,2016
4. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study;Amiot;Aliment Pharmacol Therapeut,2017
5. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease;Amiot;Clin Gastroenterol.,2016
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Today and tomorrow: the use of biomarkers in inflammatory bowel disease;Canadian IBD Today;2023-10-30
2. Using fluorescently labeled vedolizumab to visualize local drug distribution during colonoscopy and identify mucosal target cells in patients with inflammatory bowel disease;2023-10-26
3. Mucosal α4β7+ Lymphocytes and MAdCAM+ Venules Predict Response to Vedolizumab in Ulcerative Colitis;Inflammatory Bowel Diseases;2023-07-12
4. Pharmacologic Management of Monogenic and Very Early Onset Inflammatory Bowel Diseases;Pharmaceutics;2023-03-17
5. Epigenetic Modifications of the Nuclear Factor Kappa B Signalling Pathway and its Impact on Inflammatory Bowel Disease;Current Pharmaceutical Design;2021-10-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3